Azacitadine

DRUG4 trials

Conditions

Acute Myeloid LeukemiaAcute Myeloid Leukemia (AML)Acute Myeloid Leukemia RefractoryAcute Myeloid Leukemia, in RelapseChronic Lymphocytic Leukemia (CLL)Multiple Myeloma (MM)Non-Hodgkin Lymphoma (NHL)Small Lymphocytic Lymphoma (SLL)

Phase 1

Study Evaluating Venetoclax in Subjects With Hematological Malignancies

CompletedNCT02265731

AbbVieAcute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM) +2

Start: 2014-09-22End: 2021-03-12Updated: 2021-08-02

Venetoclax to Augment Epigenetic Modification and Chemotherapy

RecruitingNCT05317403

Medical College of WisconsinAcute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory

Start: 2023-03-31End: 2027-01-31Target: 40Updated: 2026-01-12

Phase 2

Study of Azacitidine in Combination With Pembrolizumab in R/R AML Patients and in Newly Diagnosed Older Patients

CompletedNCT02845297

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsAcute Myeloid Leukemia

Start: 2016-07-31End: 2022-12-31Updated: 2023-03-09

Phase 3

Azacytidine (Vidaza®) Versus Fludarabine and Cytarabine (Fluga Scheme) in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia

CompletedNCT02319135

PETHEMA FoundationAcute Myeloid Leukemia

Start: 2014-10-31End: 2019-10-28Updated: 2020-04-06

Blood2025-11-03

Venetoclax, Azacitidine, Vorinostat and FLAG for Pediatric Patients with Relapsed/Refractory Acute Myeloid Leukemia

Blood2024-11-05

Venetoclax treatment for chronic lymphocytic leukemia/small lymphocytic leukemia in Japan: post-marketing surveillance

International Journal of Hematology2024-08-21

The Composition of Acute Myeloid Leukemia Cell Differentiation States Predicts Response to Immune Checkpoint Blockade

Blood2022-11-153 citations

Immune dysfunction signatures predict outcomes and define checkpoint blockade–unresponsive microenvironments in acute myeloid leukemia

Journal of Clinical Investigation2022-09-1390 citations

Transcriptomic Features of Immune Exhaustion and Senescence Predict Outcomes and Define Checkpoint Blockade-Unresponsive Microenvironments in Acute Myeloid Leukemia

Blood2021-11-051 citations

Venetoclax plus azacitidine in Japanese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy

Japanese Journal of Clinical Oncology2021-10-2729 citations

The Mutational Landscape of Acute Myeloid Leukaemia Predicts Responses and Outcomes in Elderly Patients from the PETHEMA-FLUGAZA Phase 3 Clinical Trial

Cancers2021-05-1812 citations

Venetoclax in combination with azacitidine in Japanese patients with acute myeloid leukaemia: phase 1 trial findings

Japanese Journal of Clinical Oncology2021-03-049 citations

Phase 1/2 study of venetoclax, a BCL-2 inhibitor, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.

2020-10-2319 citations

Mutational Profiling Predicts Clinical Outcomes to Azacytidine and Low Dose Cytarabine Plus Fludarabine (FLUGA) in Elderly Acute Myeloid Leukemia Patients Enrolled in the Pethema Phase III Flugaza Trial

Blood2019-11-13

PB1890 VENETOCLAX ALONE OR IN COMBINATION WITH RITUXIMAB FOR JAPANESE PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA

HemaSphere2019-06-01

Preliminary Results of the Flugaza Trial: A Phase III Randomized, Open Label Study Comparing Azacytidine Versus Fludarabine and Cytarabine (FLUGA Scheme) in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia

Blood2016-12-021 citations

Azacitadine

Sponsors

Conditions

Phase 1

Phase 2

Phase 3

Related Papers